Navigation Links
PSA Doubling Predicts Prostate Cancer Recurrence

A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical// prostatectomy.

In a new Mayo Clinic study, the concept of PSA doubling time (DT) is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer. Doubling time is defined as the duration for PSA levels in the blood to increase by 100 percent.

Mayo’s study concludes that patients with a PSA doubling time of less than three months after therapy are at imminent risk of death from prostate cancer. Patients with a doubling time of three to 12 months are at a significant risk for the development of systematic disease and cancer-specific death.

According to the authors, the new findings should prompt physicians whose patients have doubling times of less than one year to treat them with systematic therapies. Patients with PSA doubling times of one to 10 years are more likely to have a local rather than systematic recurrence, and patients with a PSA doubling time of greater than 10 years are at a low risk of recurrence.

Source-Newswise/B
'"/>




Page: 1

Related medicine news :

1. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
2. V P Singh Proposes Doubling Of Medical Seats
3. Surge of HIV Cases in Taiwan Prompts Doubling in Expenditure for HIV Prevention
4. Restricted Activity Predicts Disability
5. Fitness Level Predicts Stroke
6. PSA Can Predicts The Treatment Response In Advanced Prostate Cancer
7. Being Teased Predicts Poor Psychological Functioning in Youth With Cleft Lip
8. Model Predicts Colon Cancer Inheritable Genetic Defects
9. Formula Predicts Osteoporotic Fracture Risk
10. Computer Tool Predicts Effectiveness Of Microbicides
11. New Genetic Test Predicts Eye-Cancer Patients Futures
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2019)... (PRWEB) , ... June 24, 2019 , ... ... adolescents and adults, today announced the restructuring of the Strategic Advisory Board (SAB) ... to meet the demand for behavioral health care. , We are ...
(Date:6/20/2019)... ... June 20, 2019 , ... ... IT services, announced that Angel Rosa has been appointed as Senior Vice President ... developing and implementing new services, growing and nurturing high performing teams, and driving ...
(Date:6/20/2019)... ... , ... The 2019 Colorado Classic® presented by VF Corporation will showcase its ... elite teams, organizers announced today. The top-four domestic teams in USA Cycling’s Pro ... , The standalone pro women’s road race has received commitments from 16 teams, ...
(Date:6/19/2019)... ... ... CEO Steven C. Bilt of Smile Brands Inc. has won a Glassdoor ... , one of the world’s largest job and recruiting sites, released its annual report ... throughout North America and parts of Europe. , Smile Brands, a leading dental support ...
(Date:6/19/2019)... ... June 19, 2019 , ... The FSH Society announced ... in Marseille, France. The conference is widely seen as the premier global platform ... Nearly 200 researchers, clinicians, industry representatives and patient advocates are attending. , Researchers ...
Breaking Medicine News(10 mins):
(Date:6/20/2019)... NEW YORK (PRWEB) , ... June 20, 2019 ... ... showed signs that exposure to dust from the World Trade Center site had ... according to a study by Mount Sinai researchers in Molecular Cancer Research in ...
(Date:6/20/2019)... ... June 20, 2019 , ... ... clinical trials, today announced its scientific and technological experts will present a series ... Information Association (DIA) Annual Meeting in San Diego, June 23-27. , ERT’s ...
(Date:6/20/2019)... N.C. (PRWEB) , ... June 20, 2019 , ... ... (SCTM) demonstrates how preconditioning mesenchymal stem cells (MSCs) enhances their ability to treat ... to developing more effective MSC treatments for clinical application, according to Ben Antebi, ...
Breaking Medicine Technology: